234 related articles for article (PubMed ID: 27001435)
61. Somatostatin receptor expression in parathyroid neoplasms.
Storvall S; Leijon H; Ryhänen E; Louhimo J; Haglund C; Schalin-Jäntti C; Arola J
Endocr Connect; 2019 Aug; 8(8):1213-1223. PubMed ID: 31336364
[TBL] [Abstract][Full Text] [Related]
62. Genetic profiling as a clinical tool in advanced parathyroid carcinoma.
Kutahyalioglu M; Nguyen HT; Kwatampora L; Clarke C; Silva A; Ibrahim E; Waguespack SG; Cabanillas ME; Jimenez C; Hu MI; Sherman SI; Kopetz S; Broaddus R; Dadu R; Wanland K; Williams M; Zafereo M; Perrier N; Busaidy NL
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1977-1986. PubMed ID: 31309300
[TBL] [Abstract][Full Text] [Related]
63. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs.
Hu Y; Zhang X; Cui M; Wang M; Su Z; Liao Q; Zhao Y
RNA Biol; 2019 Sep; 16(9):1228-1236. PubMed ID: 31213128
[TBL] [Abstract][Full Text] [Related]
64. MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.
Bollerslev J; Schalin-Jäntti C; Rejnmark L; Siggelkow H; Morreau H; Thakker R; Sitges-Serra A; Cetani F; Marcocci C
Eur J Endocrinol; 2019 Sep; 181(3):P1-P19. PubMed ID: 31176307
[TBL] [Abstract][Full Text] [Related]
65. Current concepts in parathyroid carcinoma: a single Centre experience.
Ferraro V; Sgaramella LI; Di Meo G; Prete FP; Logoluso F; Minerva F; Noviello M; Renzulli G; Gurrado A; Testini M
BMC Endocr Disord; 2019 May; 19(Suppl 1):46. PubMed ID: 31142320
[TBL] [Abstract][Full Text] [Related]
66. Recurrent Metastasized Parathyroid Carcinoma-Long-Term Remission After Combined Treatments With Surgery, Radiotherapy, Cinacalcet, Zoledronic Acid, and Temozolomide.
Storvall S; Ryhänen E; Bensch FV; Heiskanen I; Kytölä S; Ebeling T; Mäkelä S; Schalin-Jäntti C
JBMR Plus; 2019 Apr; 3(4):e10114. PubMed ID: 31044184
[TBL] [Abstract][Full Text] [Related]
67. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
68. Parathyroid Carcinoma Causing Mild Hyperparathyroidism in Neurofibromatosis Type 1: A Case Report and Systematic Review.
Triggiani V; Castellana M; Basile P; Renzulli G; Giagulli VA
Endocr Metab Immune Disord Drug Targets; 2019; 19(3):382-388. PubMed ID: 30198445
[TBL] [Abstract][Full Text] [Related]
69. Case report: lady with bone pains for 5 years-parathyroid carcinoma.
Rizwan A; Jamal A; Uzzaman M; Fatima S
BMC Res Notes; 2018 Aug; 11(1):617. PubMed ID: 30157930
[TBL] [Abstract][Full Text] [Related]
70. Verification of candidate microRNA markers for parathyroid carcinoma.
Hu Y; Zhang X; Cui M; Su Z; Wang M; Liao Q; Zhao Y
Endocrine; 2018 May; 60(2):246-254. PubMed ID: 29453660
[TBL] [Abstract][Full Text] [Related]
71. Atypical manifestation of parathyroid carcinoma with late-onset distant metastases.
Tsoli M; Angelousi A; Rontogianni D; Stratakis C; Kaltsas G
Endocrinol Diabetes Metab Case Rep; 2017; 2017():. PubMed ID: 29118988
[TBL] [Abstract][Full Text] [Related]
72. Persistent and recurrent hyperparathyroidism.
Guerin C; Paladino NC; Lowery A; Castinetti F; Taieb D; Sebag F
Updates Surg; 2017 Jun; 69(2):161-169. PubMed ID: 28434176
[TBL] [Abstract][Full Text] [Related]
73. Less is more: time to expand the indications for minimally invasive video-assisted parathyroidectomy.
Bakkar S; Matteucci V; Corsini C; Pagliaro S; Miccoli P
J Endocrinol Invest; 2017 Sep; 40(9):979-983. PubMed ID: 28374221
[TBL] [Abstract][Full Text] [Related]
74. Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.
Walls GV; Stevenson M; Lines KE; Newey PJ; Reed AAC; Bowl MR; Jeyabalan J; Harding B; Bradley KJ; Manek S; Chen J; Wang P; Williams BO; Teh BT; Thakker RV
Oncogene; 2017 Jul; 36(28):4025-4036. PubMed ID: 28288139
[TBL] [Abstract][Full Text] [Related]
75. Association of parathyroid carcinoma and thyroid disorders: A clinical review.
Campennì A; Giovinazzo S; Pignata SA; Di Mauro F; Santoro D; Curtò L; Trimarchi F; Ruggeri RM; Baldari S
Endocrine; 2017 Apr; 56(1):19-26. PubMed ID: 27744598
[TBL] [Abstract][Full Text] [Related]
76. Update on parathyroid carcinoma.
Cetani F; Pardi E; Marcocci C
J Endocrinol Invest; 2016 Jun; 39(6):595-606. PubMed ID: 27001435
[TBL] [Abstract][Full Text] [Related]
77. Parathyroid Carcinoma.
Cetani F; Pardi E; Marcocci C
Front Horm Res; 2019; 51():63-76. PubMed ID: 30641523
[TBL] [Abstract][Full Text] [Related]
78. Parathyroid carcinoma: a clinical and genetic perspective.
Cetani F; Pardi E; Marcocci C
Minerva Endocrinol; 2018 Jun; 43(2):144-155. PubMed ID: 28949121
[TBL] [Abstract][Full Text] [Related]
79. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
[TBL] [Abstract][Full Text] [Related]
80. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
